Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals... Show more
Purple Biotech Ltd. is a clinical-stage immunotherapy company headquartered in Rehovot, Israel, focused on next-generation antibody therapies for solid-tumor cancers. Its strategic center of gravity is now the CAPTN-3 platform, which produces "masked" tri-specific antibodies designed to bind a tumor-associated antigen while simultaneously engaging T cells and NK cells. The capping design is intended to keep immune activation localized to the tumor, potentially widening the therapeutic window (the gap between an effective dose and a toxic one) relative to conventional T-cell engagers.
The lead candidate, IM1240, targets the 5T4 antigen, while the second candidate, IM1305, targets TROP2. Both are aimed at solid tumors associated with advanced disease and poor outcomes. Positive preclinical data presented at the ESMO Immuno-Oncology Congress 2025, along with toxicology results showing improved tolerability at doses up to 300-fold higher than a non-capped comparator, support the platform's differentiating thesis. Management has also reported commercially viable manufacturing yields, a meaningful step for a complex multi-valent antibody.
Structurally, the company has concentrated its limited resources on one platform and de-emphasized two clinical-stage assets, CM24 and NT219, whose continued development is contingent on partnering or external funding. This focus simplifies the investment case but also concentrates risk: the near-term valuation narrative now rests largely on the execution of a single preclinical-to-Phase 1 program.
The clearest growth catalyst on the horizon is the planned initiation of a Phase 1 clinical trial for IM1240. Successfully filing an investigational new drug application and dosing the first patient would mark a transition from preclinical promise to clinical validation, a threshold that typically drives re-rating in early-stage biotech. Additional preclinical data disclosures on IM1240 and IM1305 through 2026 could further shape investor sentiment.
Partnership activity is a second pivotal catalyst. Because CM24 (a CEACAM1-blocking antibody) and NT219 (a dual IRS1/2 and STAT3 inhibitor) can only advance with outside capital or a collaborator, any licensing deal or strategic investment would both validate the broader pipeline and reduce financing pressure.
Capital allocation is equally important. With roughly $9.5 million in cash at year-end 2025 and a stated runway into 2027, future equity raises could dilute existing holders but also extend the company's ability to reach clinical milestones.
On analyst sentiment, coverage is limited. H.C. Wainwright has maintained a Buy rating while lowering its 12-month price target in stages, from $34 to $30 and subsequently to $17, a signal of tempered optimism. Consensus ratings across data providers range from "Hold" to "Moderate Buy," and the thin coverage means individual revisions can carry outsized influence on the stock forecast.
Purple Biotech operates at the intersection of two active oncology themes: T-cell engagers and masked (conditionally activated) antibodies. Industry attention to cytokine release syndrome and other immune-related toxicities has increased demand for technologies that promise potency without systemic side effects, a tailwind aligned with CAPTN-3's design.
Macro conditions matter indirectly through the financing channel. Clinical-stage companies without product revenue depend on equity markets, and higher-for-longer interest rates or a risk-off environment can raise the cost of capital and pressure valuations across the biotech sector. Inflation trends influence R&D and manufacturing costs, while the regulatory climate, particularly the U.S. Food and Drug Administration's stance on novel antibody formats, will shape development timelines. Geopolitical considerations tied to the company's Israeli headquarters and operations can also periodically affect execution and investor sentiment.
For traders seeking a data-driven read on near-term direction, Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps identify whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. While it does not replace fundamental analysis, it can complement a research workflow focused on the timing and direction of moves. Consider exploring the Trend Prediction Engine to see how its AI-driven signals are currently reading PPBT alongside your own analysis.
Looking into 2026 and beyond, the defining question is whether CAPTN-3 can translate compelling preclinical data into clinical proof of concept. A successful early readout would position the platform as a differentiated player in the crowded but high-value solid-tumor immunotherapy market, while any safety or manufacturing setback could sharply reset expectations given the concentrated pipeline.
Longer-term themes include the evolution of masked-antibody science, where competitors are also pursuing conditionally activated approaches; cost-structure discipline, as a lean organization must stretch limited cash across multi-year clinical development; and capital-allocation priorities, which will hinge on whether management funds IM1240 organically, via partnerships, or through additional equity raises. Regulatory developments governing tri-specific antibody formats and the trajectory of oncology partnership activity will also be important signposts.
Consensus expectations remain modest and thinly covered, and external price targets should be read strictly as analyst projections rather than guarantees. For investors evaluating the future outlook, the key variables are clinical execution, partnering success, and the durability of the company's funding runway, each of which will shape the trajectory of the PPBT stock forecast over the medium term.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PPBT has been loosely correlated with SNTI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PPBT jumps, then SNTI could also see price increases.
| Ticker / NAME | Correlation To PPBT | 1D Price Change % | ||
|---|---|---|---|---|
| PPBT | 100% | +1.79% | ||
| SNTI - PPBT | 57% Loosely correlated | -28.68% | ||
| ATOS - PPBT | 34% Loosely correlated | -1.55% | ||
| BCYC - PPBT | 32% Poorly correlated | +0.63% | ||
| APLM - PPBT | 31% Poorly correlated | -5.37% | ||
| CCCC - PPBT | 27% Poorly correlated | -4.53% | ||
More | ||||
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology
PPBT moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PPBT as a result. In 65 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on October 30, 2026. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
The 10-day moving average for PPBT crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 169 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PPBT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PPBT entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PPBT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.172) is normal, around the industry mean (3.592). P/E Ratio (-0.027) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.